A new book by Dr. Jason Karlawish, The Problem of Alzheimer’s, shares largely untold stories the history of the Alzheimer’s crisis, discussing the science,…
Biogen’s Alzheimer’s drug aducanumab encounters another bump in the road as the FDA delays its approval decision. The Federal Drug Administration has given itself…
If aducanumab — an experimental treatment that may slow the progression of Alzheimer’s — gets FDA approval, how will the healthcare system meet the anticipated…
While Biogen’s experimental Alzheimer’s treatment aducanumab faced yet another snag recently in its convoluted path toward FDA approval, other drugs companies are catching up:…
In a surprising turn of events, the Advisory Committee of experts on Biogen’s experimental Alzheimer’s drug aducanumab recommended against FDA approval of the drug…
In an unexpected twist, the advisory committee that convened today on the experimental Alzheimer’s treatment aducanumab overwhelmingly said that drugmaker Biogen has failed to…
In yet another encouraging step toward the development of what could be the first drug approved for Alzheimer’s disease, the Federal Drug Administration today…